🎁 At RA Capital, we take fun seriously! 🎉 This holiday season, we came together to spread cheer, make memories, and give back: ✨ Wrapped loads of holiday gifts for Christmas in the City for Jake's Place and Children's Services of Roxbury ✨ Showed off our "holiday spirit" in a friendly ugly sweater competition ✨ Put our brains to the test with some spirited trivia rounds ✨ Got creative with on-theme gingerbread house decorating (RA-style, of course!) ✨ Celebrated the season with our loved ones at our annual holiday party 🎄 Wishing you all a joyful, safe, and bright holiday season! 🕊️
About us
Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital's knowledge engine is guided by our TechAtlas internal research division, and Raven, RA Capital’s company building team, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re-imagined. RA Capital has more than 150 employees and over $10 billion in assets under management.
- Website
-
http://www.racap.com
External link for RA Capital Management
- Industry
- Financial Services
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Type
- Privately Held
- Specialties
- Investment Management, Healthcare, Biotechnology, Financial Services , Venture Capital, and Lifesciences
Locations
-
Primary
Get directions
200 Berkeley Street
18th Floor
Boston, MA 02116, US
Employees at RA Capital Management
Updates
-
Kudos to Capstan Therapeutics -- their new website informs and inspires, celebrates groundbreaking innovations and shows how in vivo CAR T is transforming possibilities in healthcare. This is a great example of how storytelling meets science to create real impact. 🌟 https://lnkd.in/eXMPDWHh
-
Please join us in congratulating Laura Stoppel, Joshua Resnick, and Matthew Hammond on their promotions to Partners at RA Capital! https://lnkd.in/eHcdh47a
Peter Kolchinsky on LinkedIn: Raj and I are thrilled to share that Matthew Hammond, Joshua Resnick, and... | 67 comments
linkedin.com
-
AbbVie has completed its $1.4B acquisition of Aliada Therapeutics, marking another milestone for RA Capital's Raven (RA Ventures) healthcare incubator team and an opportunity to advance potentially disease-modifying therapies for #Alzheimer's disease. Congratulations to everyone involved!
Aliada Therapeutics is now part of AbbVie. This #acquisition expands our neuroscience pipeline with an investigational therapy in #Alzheimers disease and a novel blood-brain barrier-crossing technology. Learn more: https://bit.ly/3ON5OMh $ABBV [Video description: On-screen text reads, “Aliada Therapeutics is now part of AbbVie” followed by the AbbVie and Aliada Therapeutics logos.]
-
Congratulations to our portfolio company NewAmsterdam Pharma Corporation on their announcement today of positive topline data from their Phase 3 clinical trials of Obicetrapib. We look forward to tracking their ongoing efforts to innovate therapies for cardiovascular disease. #progress #biotech #innovation #CDV #NewTherapies
NEW PHASE 3 DATA: Topline results from our BROADWAY study—our largest Phase 3 clinical trial to date—evaluated obicetrapib, our investigational CETP inhibitor, in patients with ASCVD and/or HeFH who required additional lowering of their LDL-C levels. https://bit.ly/3VrkSCH
-
RA Capital Management's Laura Tadvalkar and Emily Minkow of RA Capital's Raven (RA Ventures) healthcare incubator are both featured in GBHNews' new Women in Biotech series! Hear their perspectives on leadership and empowering women in biotech. Check out the full series: http://bit.ly/4fRGmB1
-
-
Congratulations to the Diagonal Therapeutics team on being named the Emerging Life Science Company of the Year by the New England Venture Capital Association. We look forward to their continued efforts to pioneer new ways to discover and develop agonist antibodies. #biotech #innovation https://lnkd.in/ew-zyVzu
Diagonal Therapeutics on LinkedIn: #nevca
linkedin.com
-
🚨 Friday Biotech Insights Alert 🚨 In ONE HOUR @ 1p EDT, join RA Capital Management Principal Tess Cameron and the Biotech Hangout team for a discussion on all things biotech. Link in post below 👇
On today’s #BiotechHangout, Chris Garabedian, Josh Schimmer, Tess Cameron, Sam Fazeli and Abraham (Abe) C. discuss recent deals: $PTCT/$NVS, $OLMA/$NVS, $PSTX/Roche, data: $AMGN’s Maritide, $LLY/$NVO head-to-head trial, Roche’s TIGIT Ph3 results, plus $SNTI, $CGON, $NVCR/$ZLAB, $JANX data and other oncology movers: $RVMD & $NVCR, and more topics including executive security, latest insights on Trump nominees, CNS outlook and more: https://lnkd.in/e_v3TpSx
-
-
Congratulations to our portfolio company Janux Therapeutics on the completion of their Phase 1a trial for JANX007. We are proud to support the company and their ongoing work to bring new treatment options to patients with cancer, and look forward to following their continued efforts to apply their proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to develop novel immunotherapies.
We’re pleased to announce doses selected for Phase 1b expansion trials supported by encouraging efficacy and safety profile observed in Phase 1a dose escalation for JANX007 in #mCRPC. Join our virtual investor event today at 4:30pm ET. Read the release for more details and to register for the event: https://lnkd.in/g39hJMwH #JANX #TCellEngagers #cancer #oncology #immunotherapy #immunomodulator #immunooncology #clinicaltrial #mCRPC #prostatecancer
-
Applications for #Science2Startup are open for a few more days! Submit your #startup idea by Dec 2nd for an opportunity to present to top #biotech and #pharma execs, VCs and entrepreneurs. Apply now: https://lnkd.in/e7bPwMzX
-